



## SciTech Development, LLC

### FOR IMMEDIATE RELEASE

#### SciTech Development Attending 37th Annual J.P. Morgan Healthcare Conference

(GROSSE POINTE FARMS, MI) December 1, 2018 – SciTech Development is pleased to announce that Earle Holsapple, President of SciTech Development LLC, will be attending the J.P. Morgan Healthcare Conference in San Francisco January 7 - 10, 2019. Mr. Holsapple will be meeting with investors and healthcare industry leaders at the conference; and, participating in the BIO One-on-One Partnering™ @ JPM.

#### About SciTech Development

SciTech Development, LLC is a clinical stage, biopharmaceutical company that has developed a unique, immune oncology (IO), intravenously (IV) administered, small molecule, nano-suspension version of the well-known anticancer agent, fenretinide. Fenretinide has been shown, in extensive clinical trials, to be a safe and effective therapeutic drug with targeted cancer destroying activity when blood plasma levels (bioavailability) reach a well-established baseline for several days, an outcome inconsistently realized in the past. This lead product was made possible by SciTech's discovery of a new delivery system (SciTech Delivery Vehicle - SDV) to enable IV delivery of water-insoluble drugs. The combination of SDV and fenretinide has led to SciTech's first drug product, ST-001, that holds the promise of improving and saving many lives. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech's nano-delivery technology and oncology drug product ST-001 is available at <https://www.scitechdevelopment.com/>

**For More Information:** Earle T. Holsapple, President  
SciTech Development, LLC  
(313) 938-5517



###